Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
US Department of Justice
Chinese Patent Office
Argus Health
Express Scripts
Cipla
Cerilliant

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021775

« Back to Dashboard

NDA 021775 describes ENTEREG, which is a drug marketed by Cubist Pharms and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ENTEREG profile page.

The generic ingredient in ENTEREG is alvimopan. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alvimopan profile page.
Summary for 021775
Tradename:ENTEREG
Applicant:Cubist Pharms
Ingredient:alvimopan
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 021775
Mechanism of ActionOpioid Antagonists
Suppliers and Packaging for NDA: 021775
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ENTEREG alvimopan CAPSULE;ORAL 021775 NDA Merck Sharp & Dohme Corp. 67919-020 N 67919-020-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength12MG
Approval Date:May 20, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Nov 29, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING OR PREVENTING ILEUS
Patent:➤ Try a Free TrialPatent Expiration:Jul 31, 2030Product Flag?Substance Flag?Delist Request?Y
Patented Use:ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
Patent:➤ Try a Free TrialPatent Expiration:Jun 18, 2029Product Flag?Substance Flag?Delist Request?Y
Patented Use:TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

Expired US Patents for NDA 021775

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Accenture
Chubb
US Department of Justice
Daiichi Sankyo
Cipla
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.